Reference : Les thérapies innovantes au CHU dans les maladies inflammatoires chroniques de l'intesti...
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
http://hdl.handle.net/2268/23741
Les thérapies innovantes au CHU dans les maladies inflammatoires chroniques de l'intestin (MICI)
French
[en] Innovative Therapies in Inflammatory Bowel Disease at the Chu
Belaiche, Jacques mailto [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie]
Chapelier, Nathalie mailto [Centre Hospitalier Universitaire de Liège - CHU > > Rhumatologie >]
Wertz, Sylvie mailto [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Louis, Edouard mailto [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie >]
2007
Revue Médicale de Liège
62 Spec No
63-7
Yes (verified by ORBi)
0370-629X
[en] Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis are frequent illnesses in western countries. They have a dramatic impact on the health-related quality of life. The new biological treatments developed for these diseases are potentially very effective, but are also expensive and may have significant side effects. In the present paper, the authors describe new biological therapies used during the past 10 years at the CHU. More than 20 therapeutic protocols were implemented. These protocols have given the patients the opportunity to gain very rapid access to new efficient therapies, to benefit from promising techniques for the evaluation of their pathology and to be submitted to a close follow-up that frequently called their treatment into question in the light of the most innovative options.
http://hdl.handle.net/2268/23741

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Les thérapies innovantes au CHU dans les maladies inflamm... 2007 RMLg.pdfPublisher postprint341.68 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.